Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.